Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors

Patients with advanced melanoma treated with immune checkpoint inhibitors can experience ongoing disease control after treatment discontinuation without subsequent systemic anticancer therapy. We previously defined a novel outcome, treatment-free survival (TFS), as the time between protocol therapy...

Descripción completa

Detalles Bibliográficos
Autores principales: Mantia, Charlene M., Werner, Lillian, Stwalley, Brian, Ritchings, Corey, Tarhini, Ahmad A., Atkins, Michael B., McDermott, David F., Regan, Meredith M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Original Articles: Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8691370/
https://www.ncbi.nlm.nih.gov/pubmed/34855329
http://dx.doi.org/10.1097/CMR.0000000000000793

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8691370/
https://www.ncbi.nlm.nih.gov/pubmed/34855329
http://dx.doi.org/10.1097/CMR.0000000000000793

Ejemplares similares